In June, the Food and Drug Administration approved the first vaccine developed to protect women against cervical cancer. Known as Gardasil and developed by Merck & Co., the drug is highly effective against four types of human papillomavirus, including two that cause cervical cancer.
In June, the Food and Drug Administration approved the first vaccine developed to protect women against cervical cancer. Known as Gardasil and developed by Merck & Co., the drug is highly effective against four types of human papillomavirus, including two that cause cervical cancer.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization has recommended that the vaccination series be given routinely to girls aged 11 to 12. It also noted that the series can be given to girls as early as 9 years of age at the discretion of physicians, and to girls and women who are 13 to 26 years old. The vaccine should be administered before the onset of sexual activity (before women are exposed to the virus), but women who are sexually active may still be vaccinated.
Controversy surrounds the drug already, as the cost has raised concerns that lower-income women may not be able to afford the drug, according to The Washington Post (6/9/06)-the vaccine will cost $120 per dose and protection will require three doses over 6 months). Moreover, social conservatives, who advocate abstinence as the best way to avoid getting HPV, oppose the mandatory use of vaccination. In contrast, women's and public health groups support early and mandatory vaccinations. Such decisions, though, will be made on a state-by-state basis.
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More